770 related articles for article (PubMed ID: 23533264)
41. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.
Wright KM
Oncology (Williston Park); 2020 Oct; 34(10):406-406;431. PubMed ID: 33058106
[TBL] [Abstract][Full Text] [Related]
42. Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma.
Shi G; Luo Y; Yu Z; Wang Y; Zhu B
Invest New Drugs; 2022 Aug; 40(4):858-860. PubMed ID: 35524867
[TBL] [Abstract][Full Text] [Related]
43. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
44. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
45. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Hayashi T; Odintsov I; Smith RS; Ishizawa K; Liu AJW; Delasos L; Kurzatkowski C; Tai H; Gladstone E; Vojnic M; Kohsaka S; Suzawa K; Liu Z; Kunte S; Mattar MS; Khodos I; Davare MA; Drilon A; Cheng E; Stanchina E; Ladanyi M; Somwar R
Dis Model Mech; 2020 Dec; 14(2):. PubMed ID: 33318047
[TBL] [Abstract][Full Text] [Related]
46. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with
Bradford D; Larkins E; Mushti SL; Rodriguez L; Skinner AM; Helms WS; Price LSL; Zirkelbach JF; Li Y; Liu J; Charlab R; Turcu FR; Liang D; Ghosh S; Roscoe D; Philip R; Zack-Taylor A; Tang S; Kluetz PG; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 Apr; 27(8):2130-2135. PubMed ID: 33239432
[TBL] [Abstract][Full Text] [Related]
47. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
48. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
[TBL] [Abstract][Full Text] [Related]
49. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Jang JS; Lee A; Li J; Liyanage H; Yang Y; Guo L; Asmann YW; Li PW; Erickson-Johnson M; Sakai Y; Sun Z; Jeon HS; Hwang H; Bungum AO; Edell ES; Simon VA; Kopp KJ; Eckloff B; Oliveira AM; Wieben E; Aubry MC; Yi E; Wigle D; Diasio RB; Yang P; Jen J
Sci Rep; 2015 May; 5():9755. PubMed ID: 25985019
[TBL] [Abstract][Full Text] [Related]
50. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
Nguyen L; Monestime S
Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
[TBL] [Abstract][Full Text] [Related]
51. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
GrĂ¼llich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract][Full Text] [Related]
52. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.
Lin C; Wang S; Xie W; Zheng R; Gan Y; Chang J
Oncotarget; 2016 Sep; 7(37):59236-59244. PubMed ID: 27494860
[TBL] [Abstract][Full Text] [Related]
53. Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.
Nokihara H; Nishio M; Yamamoto N; Fujiwara Y; Horinouchi H; Kanda S; Horiike A; Ohyanagi F; Yanagitani N; Nguyen L; Yaron Y; Borgman A; Tamura T
Clin Lung Cancer; 2019 May; 20(3):e317-e328. PubMed ID: 30718102
[TBL] [Abstract][Full Text] [Related]
54. Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing.
Zhang X; Li Y; Liu C; Wang W; Li M; Lv D; Sun G; Chen H; Dong X; Miao Z; Yao M; Wang K; Tian H
Lung Cancer; 2018 Apr; 118():27-29. PubMed ID: 29571998
[TBL] [Abstract][Full Text] [Related]
55. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
56. A novel PIBF1-RET gene fusion identified from a stage IA lung adenocarcinoma: A case report.
Zhao W; Sun J; Zhu H; Zhao G
Medicine (Baltimore); 2023 Jul; 102(29):e34305. PubMed ID: 37478265
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
Song Z; Yu X; Zhang Y
Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
[TBL] [Abstract][Full Text] [Related]
58. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.
Saito M; Shimada Y; Shiraishi K; Sakamoto H; Tsuta K; Totsuka H; Chiku S; Ichikawa H; Kato M; Watanabe S; Yoshida T; Yokota J; Kohno T
Cancer Res; 2015 Jun; 75(11):2264-71. PubMed ID: 25855381
[TBL] [Abstract][Full Text] [Related]
59. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
[TBL] [Abstract][Full Text] [Related]
60. Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Lee MS; Kim RN; I H; Oh DY; Song JY; Noh KW; Kim YJ; Yang JW; Lira ME; Lee CH; Lee MK; Kim YD; Mao M; Han J; Kim J; Choi YL
Oncotarget; 2016 Jun; 7(24):36101-36114. PubMed ID: 27150058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]